A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant Melanoma

This study is ongoing, but not recruiting participants.
Information provided by (Responsible Party):
Array BioPharma
ClinicalTrials.gov Identifier:
First received: April 14, 2011
Last updated: November 20, 2015
Last verified: November 2015
CLGX818X2101 is a first-time in-human, phase I study to establish the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) of daily administered LGX818 (daily, twice daily and/or every-other-day), a RAF kinase inhibitor. Patients with locally advanced or metastatic melanoma harboring the BRAF V600 mutation (during dose escalation phase and expansion phase) and patients with metastatic colorectal cancer harboring the BRAF V600 mutation (during the expansion phase) will be enrolled. The study consists of a dose escalation part were cohorts of patients will receive escalating oral doses of LGX818, followed by a safety dose expansion part were patients will be treated with oral dose of LGX818 given at the MTD or RP2D.

Condition Intervention Phase
Melanoma and Metastatic Colorectal Cancer
Drug: LGX818
Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase I, Multicenter, Open-label, Dose-escalation Study of Oral LGX818 in Adult Patients With Locally Advanced or Metastatic BRAF Mutant Melanoma

Resource links provided by NLM:

Further study details as provided by Array BioPharma:

Primary Outcome Measures:
  • Incidence of Dose Limiting Toxicities [ Time Frame: Approximately every 8 weeks (up to 2 years) ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Number and nature of Adverse events and clinical activity [ Time Frame: Approximately 3 years ] [ Designated as safety issue: Yes ]
  • Pharmacokinetic profile of LGX818 [ Time Frame: Approximately 2 years ] [ Designated as safety issue: No ]
    LGX818 Plasma concentration

  • Tumor response per RECIST [ Time Frame: Approximately 3 years ] [ Designated as safety issue: No ]
    This includes duration of response, time to response, progression free survival and overall survival.

  • Baseline molecular status [ Time Frame: Approximately 3 years ] [ Designated as safety issue: No ]
    Baseline molecular status (mutation/ amplification/ expression) in tumor tissue of potential predictive markers

Enrollment: 107
Study Start Date: September 2011
Estimated Primary Completion Date: November 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: LGX818 - Dose escalation Drug: LGX818
Experimental: LGX818 - Dose Expansion at MTD or RP2D Drug: LGX818


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

For the dose escalation phase:

  1. Histologically confirmed diagnosis of locally advanced or metastatic melanoma (stage IIIB to IV per American Joint Committee on Cancer [AJCC]). For the dose expansion phase: (i) Histologically confirmed diagnosis of locally advanced or metastatic melanoma (stage IIIB to IV per American Joint Committee on Cancer [AJCC]), or (ii) confirmed diagnosis and non-resectable advanced metastatic colorectal cancer (mCRC) for which no further effective standard therapy exists.
  2. Written documentation of BRAF V600E mutation, or any other BRAF V600 mutation.
  3. Evidence of measurable disease

Exclusion Criteria:

  1. Previous therapy with a MEK inhibitor.
  2. Symptomatic or untreated leptomeningeal disease.
  3. Symptomatic or untreated brain metastasis.Patients previously treated for these conditions that are asymptomatic in the absence of corticosteroid therapy are allowed to enroll. Brain metastasis must be stable with verification by imaging.
  4. Known acute or chronic pancreatitis.
  5. Clinically significant cardiac disease
  6. Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral LGX818
  7. Previous or concurrent malignancy. Exceptions to this exclusion criteria include: adequately treated basal cell or squamous cell skin cancer; in situ carcinoma of the cervix, treated curatively and without evidence of recurrence for at least 3 years prior to study entry; or other solid tumor treated curatively, and without evidence of recurrence for at least 3 years prior to study entry.
  8. Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test (> 5 mIU/mL).
  9. History of thromboembolic or cerebrovascular events within the last 6 months

Other protocol-defined inclusion/exclusion criteria may apply

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01436656

United States, Florida
H. Lee Moffitt Cancer Center & Research Institute Moffitt SC
Tampa, Florida, United States, 33612
United States, Massachusetts
Massachusetts General Hospital Mass General 2
Boston, Massachusetts, United States, 02114
Australia, New South Wales
Array BioPharma Investigative Site
Westmead, New South Wales, Australia, 2145
Australia, Victoria
Array BioPharma Investigative Site
Parkville, Victoria, Australia, 3050
Array BioPharma Investigative Site
Toulouse Cedex 9, France, 31059
Array BioPharma Investigative Site
Villejuif Cedex, France, 94805
Array BioPharma Investigative Site
Chuo-ku, Tokyo, Japan
Array BioPharma Investigative Site
Oslo, Norway, NO-0424
Array BioPharma Investigative Site
Barcelona, Catalunya, Spain, 08035
Array BioPharma Investigative Site
Barcelona, Catalunya, Spain, 08036
Array BioPharma Investigative Site
Madrid, Spain, 28050
Array BioPharma Investigative Site
Chur, Switzerland, 7000
Array BioPharma Investigative Site
Zuerich, Switzerland, 8091
Sponsors and Collaborators
Array BioPharma
  More Information

No publications provided

Responsible Party: Array BioPharma
ClinicalTrials.gov Identifier: NCT01436656     History of Changes
Other Study ID Numbers: CLGX818X2101, 2011-000556-42
Study First Received: April 14, 2011
Last Updated: November 20, 2015
Health Authority: United States: Food and Drug Administration
France: ANSM
Norway: NOMA
Switzerland: Swiss Medic
Spain: Agencia Espa?ola de Medicamentos y Productos Sanitarios

Keywords provided by Array BioPharma:
BRAF mutant,
BRAF mutated,
RAF kinase inhibitor
BRAF V600 mutation

Additional relevant MeSH terms:
Neoplasms by Histologic Type
Neoplasms, Germ Cell and Embryonal
Neoplasms, Nerve Tissue
Neuroectodermal Tumors
Neuroendocrine Tumors
Nevi and Melanomas

ClinicalTrials.gov processed this record on November 25, 2015